← Leaderboards
Stanley Watowich
Ridgeline Therapeutics, Llc
$657,602
Attributed
$657,602
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$657,602 · 2
By mechanism
R41$657,602 · 2
Top collaborators
No co-investigators on record.
Most similar at Ridgeline Therapeutics, Llc
Same institution · by research overlap
- Harshini Neelakantan$5,955,890
- Andrea Leah Wiley$161,216
Others in their field
Other Emerging Leaders on “Effective Therapy”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$69,114,853
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Yunda Huang · Fred Hutchinson Cancer Center$51,679,442
Research focus
Effective TherapyIn VivoComparativeDrug KineticsEnzymesIn VitroCardiacComorbidityDoseDrug Effect DisorderEfficacy StudyAcuteFundingInhibitor/AntagonistAmericanAdultChemistryAnimalsAdverse EffectsDietDrug CandidateDrug DevelopmentAffectLead
Grant awards (2)
Dose-ranging safety and efficacy studies to advance novel mechanism-of-action drug candidates to reverse age-related muscle degeneration$357,630
R41 · FY2018 · AG · contact PI
Dose-ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetes$299,972
R41 · FY2018 · DK · contact PI